About

Nanowear is the leading developer of patented, textile-based nanosensor technology with applications across a broad array of medical conditions and chronic disease states. The company’s proprietary technology provides medical professionals with accurate and continuous diagnostic data through a wearable fabric that is cost-effective and unobtrusive. Real-time data is transmitted wirelessly, streamlining the feedback process and driving outcomes. Nanowear’s core focus on innovation and next-gen technologies will continue to propel the Company towards exploring unique and groundbreaking applications for its nanosensor smart-textile technology.

 

AN INDUSTRY READY FOR NANO TECHNOLOGY

Millions of individuals suffer from chronic diseases that require continuous monitoring. Current monitoring applications tie them down to the clinic or home unit. Wearable diagnostic applications free individuals to live their lives. Clinical-grade monitoring offers peace of mind, while reliable data analytics provide medical practitioners with real-time results to make informed decisions.

Flexible and cost-effective, Nanowear delivers high-fidelity diagnostics and bridges the gap between protecting lives and freeing people to live them.


 

 

VALUES


Commitment to innovation and development nurtured through an environment that encourages curiosity, collaboration and entrepreneurship.
Organizational support and respect for all employees, customers, suppliers and partners.
Assured delivery of best-in-class products and services that enrich the medical experience, support the highest quality of life and advance the community.
Sustainable financial growth and performance without sacrificing innovation and/or ethical standards.

Team

 

Managerial Advisors

Joe Alleva

Joe Alleva

Vice Chancellor and Director of Athletics, LSU

    Esther Dyson

    Esther Dyson

    Chairman of EDventure Holdings

      Reggie Hall

      Reggie Hall

      BCG Digital Ventures

        Nick Pahade

        Nick Pahade

        CEO, CrowdHere

          Ray Pawlicki

          Ray Pawlicki

          Former CIO, Biogen and Novartis

            Steven Petrevski

            Steven Petrevski

            SVP, Technology, First Data Corporation

              Nicholas Sears M.D.

              Nicholas Sears M.D.

              Former Chief Medical Officer, MedAssets

                 

                Medical & Scientific Advisors

                Robert Harbaugh M.D.

                Robert Harbaugh M.D.

                Distinguished Professor & Chairman of Neurosurgery, Penn State University

                  Yoaav Krauthammer M.D.

                  Yoaav Krauthammer M.D.

                  Electrophysiologist, HealthEast Care System

                    Mark Kronenfeld M.D.

                    Mark Kronenfeld M.D.

                    Vice Chairman of Dept. of Anesthesiology, Maimonides Medical Center

                      David Theodoro M.D.

                      David Theodoro M.D.

                      Cardiac Surgeon & Chairman, Cardiovascular Dept., SSM Heart Institute

                        Press

                        January 5, 2018:

                        Nanowear and The Secant Group announce exclusive supply chain partnership for scaled manufacturing of proprietary cloth-based nanosensor technology

                        NEW YORK, NY – January 5, 2018 – Nanowear, the leader in cloth-based diagnostic monitoring nanosensor technology, today announced that it has entered into an exclusive, worldwide supply-chain partnership agreement with The Secant Group for scaled manufacturing and production of its medical-grade cloth-based nanosensor technology. Under the terms of the agreement, Nanowear and The Secant Group will have the collective obligation for marketing the technology and associated products. Click for full press release…

                        December 1, 2016:

                        Nanowear receives FDA clearance for its transformative remote diagnostic monitoring device differentiated by novel cloth-based nanosensor technology (SimplECG™)

                        NEW YORK, NY – December 1, 2016 – Nanowear, an early stage developer of cloth-based diagnostic monitoring nanosensor technology, today announced that it has received FDA Class II 510(k) clearance for its first product, SimplECG™, a remote cardiac monitoring undergarment. SimplECG™ collects continuous multi-channel ECG, heart rate and respiratory rate data from the garment and transfers it to a web-based portal for review by a physician, by way of a mobile application. The initial version of the product is iPhone-based. Click for full press release…

                        December 10, 2014:

                        Nanowear Appoints Industry-Leading Experts to its Newly Formed Advisory Board

                        NEW YORK, NY – December 10, 2014 – Nanowear, an emerging developer of wearable, textile-based diagnostic monitoring technology, today announced the appointment of leading medical and technology experts to its newly formed Advisory Board. The newly appointed Advisory Board will serve as a strategic resource to Nanowear as the Company continues product development and quality management in preparation for the U.S. Food and Drug Administration (FDA) approval process of its go-to-market product, a remote cardiac monitoring shirt for patients exhibiting symptoms of cardiovascular disease and potential ischemic events. Click for full press release…

                         

                        September 10, 2014:

                        Nanowear Raises $1.5M Led by Social+Capital and MAS Holdings to Disrupt Remote Medical Diagnostic Monitoring

                        NEW YORK, NY – September 10, 2014 – Nanowear Inc., an early-stage developer of wearable, textile-based diagnostic monitoring technology, today announced a $1.5M seed investment led by The Social+Capital Partnership and MAS Holdings (Pvt.) Limited, with several influential angels also participating in the round. The seed investment will fund production scaling and continued testing / validation of the company’s go-to-market product, a remote cardiac monitoring wearable base layer, in preparation for the U.S. Food and Drug Administration’s (FDA) approval process. Click for full press release...

                         

                         

                         

                        Contact

                        Contact us to learn more about how Nanowear can increase physician efficiency and patient experience while reducing the costs associated with diagnostic monitoring.

                        Thank you! I have received your message.

                        name

                        email

                        message

                        Contact Info

                        info@nanowearinc.com

                        New York, NY (HQ) | University Park, PA (R&D)